Get the Stockscreener App
47.51
1.23%
-0.59
Pre-market:
47.01
-0.50
-1.05%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $47.51, with a volume of 2.47M.
It is down -1.23% in the last 24 hours and down -21.61% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$48.10
Open:
$47.23
24h Volume:
2.47M
Relative Volume:
1.36
Market Cap:
$8.31B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
50.54
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-9.57%
1M Performance:
-21.61%
6M Performance:
-32.48%
1Y Performance:
-23.52%
1-Day Range:
$46.01
$47.77
1-Week Range:
$46.01
$53.00
52-Week Range:
$46.01
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
47.51 | 8.31B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Former Novartis Deal Chief Who Led 50+ Strategic Transactions Joins OmniAb Board - Stock Titan
Leerink Partners Adjusts Price Target on Bio-Techne to $80 From $95, Keeps Outperform Rating - marketscreener.com
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu - MSN
Bio-Techne Sets Date for Q3 2025 Financial Results: Key Details for Investors - Stock Titan
Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance
Bio-Techne (TECH) Faces Downgrade Amid NIH Funding Concerns - GuruFocus
Forecasting The Future: 6 Analyst Projections For Bio-Techne - Benzinga
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Bio-Techne stock downgraded at KeyBanc (TECH:NASDAQ) - Seeking Alpha
KeyBanc Downgrades Bio-Techne to Sector Weight From Overweight - MarketScreener
KeyBanc cuts Bio-Techne stock rating on funding concerns By Investing.com - Investing.com India
KeyBanc cuts Bio-Techne stock rating on funding concerns - Investing.com
Trading (TECH) With Integrated Risk Controls - news.stocktradersdaily.com
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Spatial Genomics and Transcriptomics Industry Analysis Report 2025, Featuring Detailed Profiles of Leading Players10x Genomics, Bruker Corp., Akoya Biosciences, and Bio-Techne Among OthersResearchAndMarkets.com - Bluefield Daily Telegraph
Techne Corp stock hits 52-week low at $56.58 amid market shifts - Investing.com
Bio-Techne Expands Collaboration With Leica To Enhance Spatial Multiomics Research Capabilities - Nasdaq
Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument - PR Newswire
Evercore ISI Adjusts Bio-Techne Price Target to $70 From $75, Maintains Outperform Rating - marketscreener.com
Is Bio-Techne Corporation Stock Underperforming the S&P 500? - Nasdaq
Is Bio-Techne Corporation Stock Underperforming The S&P 500? - Barchart.com
Bio-Techne Opens New Customer Experience Centre in Germany - Nasdaq
3 Reasons to Avoid TECH and 1 Stock to Buy Instead - Yahoo Finance
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Research Tools & Consumables Stocks Q4 Earnings: Bio-Techne (NASDAQ:TECH) Best of the Bunch - Yahoo Finance
Bio-Techne to Open New Customer Facility in Germany - Marketscreener.com
Bio-Techne's New Tech Hub Targets Major European Life Sciences Growth - Stock Titan
Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting - Quantisnow
Game-Changing Cancer Detection Technology: RNAscope Shows Superior Results in Multiple Tumors - Stock Titan
Bio-Techne Earnings Preview: What to Expect - MSN
Evercore ISI Group Initiates Coverage of Bio-Techne (TECH) with Outperform Recommendation - MSN
Evercore ISI sets Bio-Techne stock Outperform with $75 target By Investing.com - Investing.com South Africa
6 Analysts Assess Bio-Techne: What You Need To Know - Benzinga
Evercore ISI sets Bio-Techne stock Outperform with $75 target - Investing.com
Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future - TipRanks
Bio-Techne (NASDAQ:TECH) shareholders have earned a 8.3% CAGR over the last five years - Yahoo Finance
Bio-Techne (NASDAQ:TECH) Downgraded by StockNews.com to "Hold" - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Receives $82.14 Consensus Price Target from Analysts - Defense World
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Bio Techne at Barclays Conference: Strategic Growth Amid Market Challenges - Investing.com
TECH Stock Might Rise Following the Leo Shipping Announcement - Nasdaq
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Bio-Techne at Leerink’s Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com India
Techne Corp stock hits 52-week low at $58.94 amid market shifts - Investing.com India
Techne Corp stock hits 52-week low at $58.94 amid market shifts By Investing.com - Investing.com South Africa
GC Wealth Management RIA LLC Takes $805,000 Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corp (TECH) Q1 FY2025 Earnings: Revenue Surpasses Est - GuruFocus.com
Bio-Techne Begins Shipping LeoA Next Generation High-Throughput Simple Western System - Quantisnow
Bio-Techne launches high-throughput Leo System - Investing.com
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):